Neovasc (NASDAQ: CYTX) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.
Institutional & Insider Ownership
21.2% of Neovasc shares are held by institutional investors. Comparatively, 5.7% of Cytori Therapeutics shares are held by institutional investors. 0.8% of Cytori Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Neovasc and Cytori Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neovasc currently has a consensus price target of $1.25, suggesting a potential upside of 3,461.25%. Cytori Therapeutics has a consensus price target of $13.83, suggesting a potential upside of 2,565.38%. Given Neovasc’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Neovasc is more favorable than Cytori Therapeutics.
Volatility and Risk
Neovasc has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.
Valuation & Earnings
This table compares Neovasc and Cytori Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neovasc||$5.39 million||12.21||-$22.90 million||($0.37)||-0.09|
|Cytori Therapeutics||$2.69 million||1.49||-$22.68 million||($6.50)||-0.08|
Cytori Therapeutics has lower revenue, but higher earnings than Neovasc. Neovasc is trading at a lower price-to-earnings ratio than Cytori Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Neovasc and Cytori Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Neovasc Company Profile
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.